Intellipharmaceutics International Inc. (IPCIF)
Stock Price Chart
Key Info
| Market Cap | 2.94M |
| Revenue (ttm) | 3.48M |
| Net Income (ttm) | -8.08M |
| Shares Out | 23.68M |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 25 |
| Last Price | $0.1240 |
| Previous Close | $0.1300 |
| Change ($) | -0.0060 |
| Change (%) | -4.62% |
| Day's Open | 0.1203 |
| Day's Range | 0.1171 - 0.1245 |
| Day's Volume | 31,212 |
| 52-Week Range | 0.06 - 0.953 |
More Stats
| Market Cap | 2.94M |
| Enterprise Value | 4.78M |
| Earnings Date (est) | Jan 1, 1970 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 23.68M |
| Float | n/a |
| EPS (basic) | -0.37 |
| EPS (diluted) | -0.13 |
| FCF / Share | -0.31 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 713,995 |
| Short Ratio | 0.39 |
| Short % of Float | n/a |
| Beta | 1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.84 |
| PB Ratio | n/a |
| Revenue | 3.48M |
| Operating Income | -7.83M |
| Net Income | -8.08M |
| Free Cash Flow | -6.68M |
| Net Cash | -1.84M |
| Net Cash / Share | -0.08 |
| Gross Margin | 258.31% |
| Operating Margin | -225.11% |
| Profit Margin | -232.30% |
| FCF Margin | -191.87% |
| ROA | -67.02% |
| ROE | n/a |
| ROIC | 2,910.70% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.48 | 1.71 | 5.50 | 2.25 | 4.09 | 8.77 | 1.53 | 0.11 | 0.50 | 1.46 |
| Revenue Growth | 103.21% | -68.88% | 144.97% | -45.11% | -53.32% | 474.13% | 1326.33% | -78.66% | -65.61% | - |
| Gross Profit | 3.45 | 1.59 | 4.80 | 2.25 | 4.09 | 8.77 | 1.53 | 0.11 | 0.50 | 1.46 |
| Operating Income | -7.83 | -13.33 | -8.27 | -9.85 | -7.11 | -3.53 | -6.82 | -10.12 | -7.78 | -6.05 |
| Net Income | -8.08 | -13.75 | -8.86 | -10.14 | -7.44 | -3.86 | -11.50 | -6.14 | -4.88 | -5.76 |
| Shares Outstanding | 21.58 | 4.76 | 3.10 | 2.67 | 2.38 | 2.31 | 1.97 | 1.73 | 1.50 | 1.09 |
| Earnings Per Share | -0.37 | -2.89 | -2.86 | -3.80 | -3.10 | -1.70 | -5.80 | -3.60 | -3.30 | -5.30 |
| Operating Cash Flow | -6.66 | -12.51 | -6.11 | -6.25 | -3.78 | -1.71 | -6.93 | -7.65 | -6.98 | -6.19 |
| Capital Expenditures | -0.01 | -0.10 | -1.82 | -0.52 | -0.43 | -0.77 | -0.12 | -1.04 | -0.26 | -0.13 |
| Free Cash Flow | -6.68 | -12.61 | -7.93 | -6.77 | -4.21 | -2.48 | -7.05 | -8.69 | -7.24 | -6.33 |
| Cash & Equivalents | 0.06 | 6.64 | 1.90 | 4.14 | 1.76 | 4.23 | 0.76 | 0.50 | 4.82 | 0.79 |
| Total Debt | 1.90 | 1.79 | 1.29 | 1.51 | 1.55 | 1.44 | 2.15 | 0.10 | 0.14 | 0.01 |
| Net Cash / Debt | -1.84 | 4.85 | 0.61 | 2.63 | 0.20 | 2.79 | -1.39 | 0.40 | 4.68 | 0.78 |
| Assets | 3.80 | 11.47 | 7.40 | 7.97 | 5.22 | 7.88 | 4.38 | 2.47 | 6.25 | 3.27 |
| Liabilities | 7.49 | 7.37 | 7.01 | 6.86 | 5.36 | 2.97 | 10.33 | 4.24 | 9.34 | 3.17 |
| Book Value | -3.69 | 4.10 | 0.39 | 1.12 | -0.14 | 4.91 | -5.96 | -1.77 | -3.09 | 0.09 |
Company Profile
Company Details
| Full Name | Intellipharmaceutics International Inc. |
| Country | Canada |
| Employees | 33 |
| CEO | Isa Odidi |
Stock Information
| Ticker Symbol | IPCIF |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | OTCMKTS: IPCIF |
Description
Intellipharmaceutics International, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.